J&J could launch its single-dose COVID-19 vaccine in March
US pharma Johnson & Johnson (J&J) is planning to launch its single-dose COVID-19 vaccine in March, according to the company’s chief scientific officer Paul Stoffels.
In an interview with Reuters, Stoffels added that the company is expecting to have ‘clear data’ on the efficacy of its COVID-19 vaccine by either the end of January or early February.
J&J initiated a large-scale phase 3 trial of its COVID-19 vaccine in September 2020, following positive interim results from a phase 1/2a clinical study.
The phase 3 ENSEMBLE trial was launched in collaboration with the US Department of Health and Human Services’ (HHS) Biomedical Advanced Research and Development Authority (BARDA) and the US National Institute of Allergy and Infectious Diseases (NIAID).
Read more: http://www.pmlive.com/pharma_news/j_and_j_could_launch_its_single-dose_covid-19_vaccine_in_march_1361272
In an interview with Reuters, Stoffels added that the company is expecting to have ‘clear data’ on the efficacy of its COVID-19 vaccine by either the end of January or early February.
J&J initiated a large-scale phase 3 trial of its COVID-19 vaccine in September 2020, following positive interim results from a phase 1/2a clinical study.
The phase 3 ENSEMBLE trial was launched in collaboration with the US Department of Health and Human Services’ (HHS) Biomedical Advanced Research and Development Authority (BARDA) and the US National Institute of Allergy and Infectious Diseases (NIAID).
Read more: http://www.pmlive.com/pharma_news/j_and_j_could_launch_its_single-dose_covid-19_vaccine_in_march_1361272
